General form of registration statement for all companies including face-amount certificate companies

CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' DEFICIT

v3.21.2
CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' DEFICIT - USD ($)
Evolv Technologies Holdings Inc [Member]
Common Stock
Adoption of ASU 2018-07 and ASU 2019-08 (Note 1)
Evolv Technologies Holdings Inc [Member]
Common Stock
Evolv Technologies Holdings Inc [Member]
Additional Paid-in Capital
Evolv Technologies Holdings Inc [Member]
Accumulated Deficit
Evolv Technologies Holdings Inc [Member]
Adoption of ASU 2018-07 and ASU 2019-08 (Note 1)
Evolv Technologies Holdings Inc [Member]
Additional Paid-in Capital
Accumulated Deficit
Total
Balance at the beginning at Dec. 31, 2018           $ 43,441,000      
Balance at the beginning (in shares) at Dec. 31, 2018           114,375,397      
Convertible Preferred Stock [Abstract]                  
Issuance of Series B-1 convertible preferred stock, net of issuance costs of $938           $ 22,363,000      
Issuance of Series B-1 convertible preferred stock, net of issuance costs of $105 (in shares)           63,785,925      
Conversion of convertible note into Series B-1 convertible preferred stock           $ 6,595,000      
Conversion of convertible note into Series B-1 convertible preferred stock (in shares)           18,056,296      
Balance at the end at Dec. 31, 2019         $ (484,000) $ 72,883,000      
Balance at the end (in shares) at Dec. 31, 2019         484 196,217,618      
Balance at the beginning at Dec. 31, 2018   $ 23,000 $ 8,145,000 $ (46,632,000)   $ (38,464,000)      
Balance at the beginning (in shares) at Dec. 31, 2018   22,499,825              
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Issuance of warrants to purchase common stock     3,000     3,000      
Issuance of common stock upon exercise of stock options   $ 0 28,000     28,000      
Issuance of common stock upon exercise of stock options (in shares)   309,333              
Stock-based compensation expense     264,000     264,000      
Net loss attributable to common stockholders ? basic and diluted       (19,857,000)   (19,857,000)      
Balance at the end at Dec. 31, 2019   $ 23,000 7,956,000 (66,489,000)   (58,510,000)      
Balance at the end (in shares) at Dec. 31, 2019 (484) 22,809,158              
Convertible Preferred Stock [Abstract]                  
Issuance of Series B-1 convertible preferred stock, net of issuance costs of $938           $ 2,994,000      
Issuance of Series B-1 convertible preferred stock, net of issuance costs of $105 (in shares)           8,486,175      
Balance at the end at Mar. 31, 2020           $ 75,877,000      
Balance at the end (in shares) at Mar. 31, 2020           204,703,793      
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Issuance of warrants to purchase common stock     45,000     $ 45,000      
Issuance of common stock upon exercise of stock options   $ 1,000 66,000     67,000      
Issuance of common stock upon exercise of stock options (in shares)   744,710              
Stock-based compensation expense     62,000     62,000      
Net loss attributable to common stockholders ? basic and diluted       (6,430,000)   (6,430,000)      
Balance at the end at Mar. 31, 2020   $ 24,000 8,129,000 (72,919,000)   (64,766,000) $ 25,000 $ (2,000) $ 23,000
Balance at the end (in shares) at Mar. 31, 2020   23,553,868              
Balance at the beginning at Dec. 31, 2019         $ (484,000) $ 72,883,000      
Balance at the beginning (in shares) at Dec. 31, 2019         484 196,217,618      
Convertible Preferred Stock [Abstract]                  
Issuance of Series B-1 convertible preferred stock, net of issuance costs of $938           $ 2,994,000      
Issuance of Series B-1 convertible preferred stock, net of issuance costs of $105 (in shares)           8,486,175      
Balance at the end at Dec. 31, 2020           $ 75,877,000     $ 140,774,000
Balance at the end (in shares) at Dec. 31, 2020           204,703,793     14,077,350
Balance at the beginning at Dec. 31, 2019   $ 23,000 7,956,000 (66,489,000)   $ (58,510,000)      
Balance at the beginning (in shares) at Dec. 31, 2019 (484) 22,809,158              
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Issuance of warrants to purchase common stock     112,000     112,000      
Issuance of common stock upon exercise of stock options   $ 3,000 439,000     $ 442,000      
Issuance of common stock upon exercise of stock options (in shares)   3,236,374       3,236,374      
Stock-based compensation expense     662,000     $ 662,000      
Net loss attributable to common stockholders ? basic and diluted     (27,392,000) (27,392,000)   (27,392,000)      
Balance at the end at Dec. 31, 2020   $ 26,000 9,169,000 (93,881,000)   (84,686,000) 16,912,000 (11,912,000) $ 5,000,000
Balance at the end (in shares) at Dec. 31, 2020   26,045,532              
Balance at the end at Mar. 31, 2020           $ 75,877,000      
Balance at the end (in shares) at Mar. 31, 2020           204,703,793      
Balance at the beginning at Jan. 23, 2020             0 0 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Net loss attributable to common stockholders ? basic and diluted               (2,000) (2,000)
Balance at the end at Mar. 31, 2020   $ 24,000 8,129,000 (72,919,000)   $ (64,766,000) 25,000 (2,000) 23,000
Balance at the end (in shares) at Mar. 31, 2020   23,553,868              
Balance at the end at Dec. 31, 2020           $ 75,877,000     $ 140,774,000
Balance at the end (in shares) at Dec. 31, 2020           204,703,793     14,077,350
Balance at the beginning at Jan. 23, 2020             0 0 $ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Issuance of warrants to purchase common stock             1,336,000   1,336,000
Net loss attributable to common stockholders ? basic and diluted               (11,912,000) (11,912,000)
Balance at the end at Dec. 31, 2020   $ 26,000 9,169,000 (93,881,000)   $ (84,686,000) 16,912,000 (11,912,000) 5,000,000
Balance at the end (in shares) at Dec. 31, 2020   26,045,532              
Balance at the end at Mar. 31, 2021           $ 75,877,000     $ 136,691,000
Balance at the end (in shares) at Mar. 31, 2021           204,703,793     13,669,161
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Issuance of warrants to purchase common stock   $ 1,000   1,000   $ 1,000      
Issuance of common stock upon exercise of stock options   $ 4,000 451,000     $ 455,000      
Issuance of common stock upon exercise of stock options (in shares)   4,137,451       4,137,451      
Stock-based compensation expense     1,082,000     $ 1,082,000      
Net loss attributable to common stockholders ? basic and diluted       (13,755,000)   (13,755,000)   (4,082,000) $ (4,082,000)
Balance at the end at Mar. 31, 2021   $ 30,000 $ 10,703,000 $ (107,636,000)   $ (96,903,000) $ 20,994,000 $ (15,994,000) $ 5,000,000
Balance at the end (in shares) at Mar. 31, 2021   30,182,983